A prospective, multicenter, single arm, open-label, phase III study to assess the safety and efficacy of bosentan in patients with digital ulcers associated with systemic sclerosis (SSc)

Trial Profile

A prospective, multicenter, single arm, open-label, phase III study to assess the safety and efficacy of bosentan in patients with digital ulcers associated with systemic sclerosis (SSc)

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2016

At a glance

  • Drugs Bosentan (Primary)
  • Indications Systemic scleroderma; Ulcer
  • Focus Adverse reactions; Registrational
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 31 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top